Bile Duct Cancer (Cholangiocarcinoma) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Bile Duct Cancer (Cholangiocarcinoma) – Pipeline Review, H1 2017’, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)

The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects

The report assesses Bile Duct Cancer (Cholangiocarcinoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

Agios Pharmaceuticals Inc

Ariad Pharmaceuticals Inc

ArQule Inc

Array BioPharma Inc

Arrien Pharmaceuticals LLC

Aslan Pharmaceuticals Pte Ltd

AstraZeneca Plc

Bavarian Nordic A/S

Bayer AG

BeiGene (Beijing) Co Ltd

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Celgene Corp

CellAct Pharma GmbH

Cellceutix Corp

Cellular Biomedicine Group Inc

Cornerstone Pharmaceuticals Inc

CytomX Therapeutics Inc

Delcath Systems Inc

Eisai Co Ltd

Eli Lilly and Company

Exelixis Inc

F. Hoffmann-La Roche Ltd

H3 Biomedicine Inc

Halozyme Therapeutics Inc

Hutchison China MediTech Ltd

Ignyta Inc

Immodulon Therapeutics Ltd

Immunitor Inc

Incyte Corp

Innopharmax Inc

Insys Therapeutics Inc

Ipsen SA

Johnson & Johnson

Komipharm International Co Ltd

Leap Therapeutics Inc

Loxo Oncology Inc

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

NanoCarrier Co Ltd

NormOxys Inc

Novartis AG

NuCana BioMed Ltd

Oasmia Pharmaceutical AB

OncoTherapy Science Inc

Panacea Pharmaceuticals Inc

PCI Biotech Holding ASA

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Provecs Medical GmbH

Puma Biotechnology Inc

RedHill Biopharma Ltd

Sanofi

Senhwa Biosciences Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Sirnaomics Inc

Sun Pharma Advanced Research Company Ltd

SynCore Biotechnology Co Ltd

SyntheX Inc

Taiwan Liposome Company Ltd

tella Inc

Threshold Pharmaceuticals Inc

VasGene Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Bile Duct Cancer (Cholangiocarcinoma) - Overview 7

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Development 8

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 22

Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 36

Bile Duct Cancer (Cholangiocarcinoma) - Drug Profiles 70

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 584

Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 586

Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 587

Appendix 598

List of Tables

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Advenchen Laboratories LLC, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Agios Pharmaceuticals Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Ariad Pharmaceuticals Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by ArQule Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Array BioPharma Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Arrien Pharmaceuticals LLC, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by AstraZeneca Plc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Bavarian Nordic A/S, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Bayer AG, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by BeiGene (Beijing) Co Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Blueprint Medicines Corp, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Boston Biomedical Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Bristol-Myers Squibb Company, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Celgene Corp, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by CellAct Pharma GmbH, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Cellceutix Corp, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Cellular Biomedicine Group Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by CytomX Therapeutics Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Delcath Systems Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Eisai Co Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Eli Lilly and Company, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Exelixis Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by H3 Biomedicine Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Halozyme Therapeutics Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Hutchison China MediTech Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Ignyta Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Immodulon Therapeutics Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Immunitor Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Incyte Corp, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Innopharmax Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Insys Therapeutics Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Ipsen SA, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Johnson & Johnson, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Komipharm International Co Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Leap Therapeutics Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Loxo Oncology Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Mebiopharm Co Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by MedImmune LLC, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Merck & Co Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by NanoCarrier Co Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by NormOxys Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Novartis AG, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by NuCana BioMed Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Oasmia Pharmaceutical AB, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by OncoTherapy Science Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Panacea Pharmaceuticals Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by PCI Biotech Holding ASA, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Pfizer Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Pharma Mar SA, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Plexxikon Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Provecs Medical GmbH, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Puma Biotechnology Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by RedHill Biopharma Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Sanofi, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Senhwa Biosciences Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Sirnaomics Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by SynCore Biotechnology Co Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by SyntheX Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Taiwan Liposome Company Ltd, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by tella Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Threshold Pharmaceuticals Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by VasGene Therapeutics Inc, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Dormant Projects, H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Bile Duct Cancer (Cholangiocarcinoma) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports